Tesa/IPA Protocol
A combination peptide protocol pairing Tesamorelin (a GHRH analog) with Ipamorelin (a selective GHRP) to synergistically amplify pulsatile growth hormone release from the pituitary gland.
The Tesa/IPA blend combines two complementary growth hormone secretagogues: Tesamorelin (a GHRH analog that stimulates GH release from the pituitary) and Ipamorelin (a selective ghrelin mimetic/GHRP that amplifies GH pulses). This combination addresses both the GHRH and GHRP pathways for synergistic GH release. Common formulations include 5mg/5mg (1:1 ratio) and 10mg/3mg (higher Tesamorelin) variants. Tesamorelin is FDA-approved for HIV-associated lipodystrophy, while Ipamorelin remains investigational.
Mechanism of Action
The blend leverages two distinct GH-releasing pathways: Tesamorelin is a synthetic GHRH analog that directly stimulates growth hormone-releasing hormone receptors on pituitary somatotrophs, triggering GH synthesis and secretion in a pulsatile, physiological manner. Ipamorelin is a selective ghrelin receptor (GHS-R1a) agonist that amplifies GH pulses without significantly affecting cortisol or prolactin. Together, they produce synergistic GH release greater than either compound alone, while maintaining the body's natural feedback mechanisms.
Reconstitution Calculator
Tesa/IPA Protocol
The Tesa/IPA blend combines two complementary growth hormone secretagogues: Tesa
Set up a clean workspace with all supplies ready.
5x / week for weeks
Safety Profile
Safety Profile: Tesa/IPA Protocol
Common Side Effects
- Injection site reactions: redness, swelling, pain, and nodule formation (subcutaneous peptide delivery)
- Increased appetite and water retention (from GH secretagogue component)
- Headache and mild dizziness
- Paresthesias (tingling in hands/feet) from growth hormone axis stimulation
- Joint stiffness and mild edema
- Sleep disturbances or vivid dreams
Serious Adverse Effects
- Unregulated combination protocol: No clinical trials have evaluated the specific Tesa/IPA combination; risks are inferred from individual components
- IGF-1 elevation: Chronic growth hormone secretagogue use raises IGF-1, which is associated with increased cancer risk in epidemiological studies
- Glucose dysregulation: GH axis stimulation can impair insulin sensitivity, potentially worsening pre-diabetes or diabetes
- Carpal tunnel syndrome from sustained GH elevation
- Infection risk from non-sterile peptide reconstitution and injection
- Unknown long-term cardiovascular effects
Contraindications
- Active cancer or strong family history of cancer (IGF-1 concern)
- Diabetes mellitus (GH-induced insulin resistance)
- Active pituitary tumors or disorders
- Pregnancy and lactation
- Children and adolescents (may interfere with normal growth plate physiology)
- Carpal tunnel syndrome
Drug Interactions
- Insulin and oral hypoglycemics: GH secretagogues antagonize insulin; dose adjustments may be needed
- Corticosteroids: Combined effects on glucose metabolism and fluid retention
- Other GH secretagogues (MK-677, GHRP-6): Stacking increases risk of excessive GH/IGF-1 elevation
- Thyroid medications: GH axis affects T4-to-T3 conversion; may require thyroid dose adjustment
Population-Specific Considerations
- Not FDA-approved: Research peptide protocol only; no regulatory oversight for human use
- Anti-aging community: Primary user base; benefits are largely anecdotal
- Gray-market sourcing: Quality and sterility of peptides cannot be guaranteed
- IGF-1 monitoring: Users should check IGF-1 levels regularly to avoid supraphysiological range
- Cycling: Most protocols recommend cycling (e.g., 8–12 weeks on, 4 weeks off) to reduce desensitization and side effects
Pharmacokinetic Profile
Quick Start
- Typical Dose
- 200-500mcg total blend per injection
- Frequency
- Once daily (evening preferred) or twice daily for advanced protocols
- Cycle Length
- 8-16 weeks continuous
- Storage
- Reconstituted: 2-8°C, use within 4-6 weeks
Research Indications
Body Composition
Tesamorelin has demonstrated fat reduction in clinical trials; synergy with Ipamorelin may enhance effects.
Tesamorelin specifically reduces visceral adipose tissue (FDA-approved indication).
Enhanced GH promotes protein synthesis and lean tissue preservation.
Recovery & Wellness
GH secretagogues often improve deep sleep quality.
Enhanced GH supports tissue repair and recovery from exercise.
Restoring more youthful GH levels may provide anti-aging benefits.
Metabolic Health
Tesamorelin has shown improvements in lipid parameters in studies.
Increased GH leads to increased IGF-1 production.
Research Protocols
subcutaneous Injection
Subcutaneous injection, typically administered before bed or in the morning on an empty stomach. Evening dosing may enhance natural nighttime GH pulse. Avoid eating 2-3 hours before and 30-60 minutes after injection for optimal results.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Standard protocol (5/5 blend) | 200-400mcg total | Once daily (evening) | —(Route: SubQ) |
| Enhanced protocol (10/3 blend) | 300-500mcg total | Once daily (evening) | —(Route: SubQ) |
| Twice daily (advanced) | 200-300mcg per dose | Morning and evening | —(Route: SubQ) |
Reconstitution Guide (mg vial + mL BAC water)
- Clean vial top with alcohol pad
- Add 2mL bacteriostatic water for convenient dosing
- Gently swirl - do not shake
- Solution should appear clear
- Label with date and concentration
- Store refrigerated immediately
- Use within 4-6 weeks
Interactions
Peptide Interactions
Different mechanisms; can complement for healing with GH support.
Different pathways; some combine for body composition goals.
Both Tesamorelin and CJC-1295 are GHRH analogs; combining may cause excessive stimulation.
What to Expect
What to Expect
Improved sleep quality often noticed first; initial GH response
Enhanced recovery; subtle body composition changes beginning
Noticeable fat loss (especially visceral); improved energy
Full body composition benefits; continued improvements
Safety Profile
Common Side Effects
- Injection site reactions (redness, itching)
- Water retention (usually transient)
- Tingling or numbness in extremities
- Joint stiffness
- Increased hunger (Ipamorelin effect)
Contraindications
- Active malignancy (GH may promote tumor growth)
- Diabetic retinopathy
- Pregnancy or breastfeeding
- Pituitary disorders
- Hypersensitivity to components
Discontinue If
- Severe injection site reactions
- Significant swelling or edema
- Signs of glucose dysregulation
- Severe joint pain
- Allergic reactions
Quality Indicators
What to look for
- Third-party testing confirming both components
- Certificate of Analysis with ratios verified
- Reputable research supplier
- Proper cold chain shipping
Caution
- Tesamorelin is FDA-approved as Egrifta - research blends are not
- Ipamorelin remains investigational
Red flags
- No Certificate of Analysis
- Cannot verify Tesamorelin:Ipamorelin ratio
- Discolored or particulate solution
References (4)
- [1]Tesamorelin FDA Approval for HIV Lipodystrophy (2010)
- [2]Tesamorelin Effects on Visceral Fat
- [3]Ipamorelin Selectivity Profile
- [4]GHRH + GHRP Synergy
Teriparatide
Teriparatide is an FDA-approved anabolic bone-building agent consisting of the first 34 amino acids of parathyroid hormone. Unlike antiresorptive osteoporosis d
Tesamorelin
Tesamorelin is a synthetic analogue of the full 44-amino acid growth hormone-releasing hormone (GHRH), modified with a trans-3-hexenoic acid group at the N-term